PLoS ONE (Jan 2013)

Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.

  • Sandra M Saldana,
  • Heng-Huan Lee,
  • Frank J Lowery,
  • Yekaterina B Khotskaya,
  • Weiya Xia,
  • Chenyu Zhang,
  • Shih-Shin Chang,
  • Chao-Kai Chou,
  • Patricia S Steeg,
  • Dihua Yu,
  • Mien-Chie Hung

DOI
https://doi.org/10.1371/journal.pone.0073406
Journal volume & issue
Vol. 8, no. 9
p. e73406

Abstract

Read online

Brain metastasis is a common cause of mortality in cancer patients, yet potential therapeutic targets remain largely unknown. The type I insulin-like growth factor receptor (IGF-IR) is known to play a role in the progression of breast cancer and is currently being investigated in the clinical setting for various types of cancer. The present study demonstrates that IGF-IR is constitutively autophosphorylated in brain-seeking breast cancer sublines. Knockdown of IGF-IR results in a decrease of phospho-AKT and phospho-p70s6k, as well as decreased migration and invasion of MDA-MB-231Br brain-seeking cells. In addition, transient ablation of IGFBP3, which is overexpressed in brain-seeking cells, blocks IGF-IR activation. Using an in vivo experimental brain metastasis model, we show that IGF-IR knockdown brain-seeking cells have reduced potential to establish brain metastases. Finally, we demonstrate that the malignancy of brain-seeking cells is attenuated by pharmacological inhibition with picropodophyllin, an IGF-IR-specific tyrosine kinase inhibitor. Together, our data suggest that the IGF-IR is an important mediator of brain metastasis and its ablation delays the onset of brain metastases in our model system.